Patents by Inventor Daniel Sutherlin

Daniel Sutherlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190112264
    Abstract: The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 28, 2017
    Publication date: April 18, 2019
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
  • Patent number: 10179767
    Abstract: The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 15, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Abid Hasan, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Shaoyi Sun, Andrew D. White, Wei Gong, Alla Yurevna Zenova, Jiuxiang Zhu
  • Publication number: 20180291014
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 11, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Phillipe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian SAFINA, Daniel SUTHERLIN, Tao WANG
  • Publication number: 20180230079
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: February 14, 2018
    Publication date: August 16, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
  • Publication number: 20180105504
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: October 31, 2017
    Publication date: April 19, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Michael Scott WILSON, Kwong Wah LAI, Philippe BERGERON, Birong ZHANG
  • Publication number: 20180029984
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 1, 2018
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 9790183
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 17, 2017
    Assignee: GENENTECH, INC.
    Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Patent number: 9694002
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 4, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu
  • Publication number: 20170087136
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variablesRA, RAA, subscipt n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Patent number: 9546164
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: January 17, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu
  • Publication number: 20160340309
    Abstract: The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Abid HASAN, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian SAFINA, Daniel SUTHERLIN, Shaoyi SUN, Andrew D. WHITE, Wei GONG, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20160152569
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 9321761
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 26, 2016
    Assignees: CURIS, INC., GENENTECH, INC.
    Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Patent number: 9278961
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 8, 2016
    Assignees: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Publication number: 20150252038
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compactions.
    Type: Application
    Filed: January 22, 2015
    Publication date: September 10, 2015
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20150105550
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Applicants: CURIS, INC., GENENTECH, INC.
    Inventors: Janet L. GUNZNER, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Publication number: 20110092461
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: December 6, 2010
    Publication date: April 21, 2011
    Inventors: Janet L. GUNZNER, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Patent number: 7888364
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: February 15, 2011
    Assignee: Curis, Inc.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Publication number: 20080076758
    Abstract: Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: April 24, 2007
    Publication date: March 27, 2008
    Applicants: Piramed Limited, Genentech, Inc.
    Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel Sutherlin, Bing-Yan Zhu
  • Publication number: 20080039459
    Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: April 24, 2007
    Publication date: February 14, 2008
    Applicants: Plramed Limited, Genentech, Inc.
    Inventors: Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson